El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

668722.pdf (463.78 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-12-15

Llicència de publicació

cc-by (c) Hernández Martinez Lapiscina et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/109662

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/1756-0500-7-910

Resum

BACKGROUND: Multiple Sclerosis (MS) is an immune-mediated disease of the Central Nervous System with two major underlying etiopathogenic processes: inflammation and neurodegeneration. The latter determines the prognosis of this disease. MS is the main cause of non-traumatic disability in middle-aged populations. FINDINGS: The MS-VisualPath Cohort was set up to study the neurodegenerative component of MS using advanced imaging techniques by focusing on analysis of the visual pathway in a middle-aged MS population in Barcelona, Spain. We started the recruitment of patients in the early phase of MS in 2010 and it remains permanently open. All patients undergo a complete neurological and ophthalmological examination including measurements of physical and disability (Expanded Disability Status Scale; Multiple Sclerosis Functional Composite and neuropsychological tests), disease activity (relapses) and visual function testing (visual acuity, color vision and visual field). The MS-VisualPath protocol also assesses the presence of anxiety and depressive symptoms (Hospital Anxiety and Depression Scale), general quality of life (SF-36) and visual quality of life (25-Item National Eye Institute Visual Function Questionnaire with the 10-Item Neuro-Ophthalmic Supplement). In addition, the imaging protocol includes both retinal (Optical Coherence Tomography and Wide-Field Fundus Imaging) and brain imaging (Magnetic Resonance Imaging). Finally, multifocal Visual Evoked Potentials are used to perform neurophysiological assessment of the visual pathway. DISCUSSION: The analysis of the visual pathway with advance imaging and electrophysilogical tools in parallel with clinical information will provide significant and new knowledge regarding neurodegeneration in MS and provide new clinical and imaging biomarkers to help monitor disease progression in these patients.

Matèries

Esclerosi múltiple, Malalties neurodegeneratives, Visió, Depressió psíquica, Ansietat

Matèries (anglès)

Multiple sclerosis, Neurodegenerative Diseases, Visión, Mental depression, Anxiety

Citació

Col·leccions

Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

HERNÁNDEZ MARTINEZ LAPISCINA, Elena, FRAGA PUMAR, Elena, GABILONDO, Iñigo, MARTINEZ-HERAS, Eloy, TORRES TORRES, Ruben, ORTIZ PÉREZ, Santiago, LLUFRIU DURAN, Sara, TERCERO URIBE, Ana, ANDORRA, Magi, FIGUERAS ROCA, Marc, LAMPERT, Erika, ZUBIZARRETA, Irati, SAIZ HINAREJOS, Albert, SÁNCHEZ DALMAU, Bernardo, VILLOSLADA, Pablo. The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS. _BMC Research notes_. 2014. Vol. 7, núm. 910. [consulta: 8 de gener de 2026]. ISSN: 1756-0500. [Disponible a: https://hdl.handle.net/2445/109662]

Exportar metadades

JSON - METS

Compartir registre